To characterize molecular and cellular damages in patients with FUS-proteinopathies, we collected de-identified post-mortem tissue samples from the Cognitive Neurology & Alzheimer's Disease Center at Northwestern University. This evidence concerns the gene FUS and early-onset autosomal dominant Alzheimer disease.